NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.01 +0.01 (+0.01%) GOLD FUTURES
2,313.30 +2.30 (+0.10%) DOW
38,188.01 +284.72 (+0.75%) Bitcoin GBP
47,263.03 +1,641.50 (+3.60%)
argenx SE (ARGNF)
| Previous close | 383.74 |
| Open | 383.74 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 383.74 - 383.74 |
| 52-week range | 341.00 - 505.00 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 22.806B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.14 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe Newswireargenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/in
- Globe Newswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that data from its Phase 3 ADHERE tri
Insider MonkeyHere’s Why argenx SE (ARGX) Pulled Back 23% in Q4
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy underperformed the Russell Midcap Growth Index and returned 13.66% (gross) and 13.44% (net) while the index return was -14.55%. In addition, please check […]
